Aptinyx Inc. develops new synthetic small molecules that can treat brain and nervous system disorders. The company's clinical-stage NYX-2925 drug addresses painful diabetic peripheral neuropathy and fibromyalgia, while NYX-783 and NYX-458 deal with post-traumatic stress disorder and Parkinson's disease cognitive impairment, respectively. Aptinyx Inc. collaborates with Allergan plc, and it is based in Evanston, Illinois.